Regeneron receives FDA’s EUA approval for its COVID-19 drug

Regeneron receives FDA’s EUA approval for its COVID-19 drug

The FDA grants EUA for Regeneron’s treatment taken by President Trump

After a week when giant pharma companies such as Moderna, Pfizer, and AstraZeneca announced that their experimental COVID-19 vaccines are effective in preventing the infection, another company filed for FDA’s approval.

The drug developed by Regeneron has received earlier today the emergency use authorization (EUA) from the Food and Drug Administration. It is the same drug that Trump used when he contracted the virus.

According to studies, Regeneron’s vaccine is effective when administrated shortly after diagnosis. The authorization allows it to be used on patients who are at risk of severe illness.

By the end of November, Regeneron will have doses for roughly 80,000 patients. By the end of January 2021, it will have doses available for 300,000 people.

The number of COVID-19 continues to rise; at the moment of writing, the US has more than 12 million confirmed cases.

After the news, Regeneron stock price went up 3.9%.

Read here about AstraZeneca’s progress!

Sources: bbc.com, Aljazeera.com

The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance and forecasts are not reliable indicators of future results.